Skip to content

End-of-season influenza vaccine effectiveness against a(H3N2) and B/Victoria in Beijing, China, 2025/26 season.

Oct 2026 · Vaccine · Vol 96, pp. 129273 · 0 citations · 19 references
Medicine

Abstract

INTRODUCTION This study aimed to estimate the end-of-season influenza vaccine effectiveness (VE) against A(H3N2) and B/Victoria in the 2025/26 season in Beijing, China.

Methods

We used a test-negative design to assess influenza VE among outpatients with influenza-like illness (ILI) enrolled through the Beijing influenza sentinel virological surveillance system from September 2025 (week 40/2025) to May 2026 (week 21/2026). Cases were ILI patients who tested positive for influenza; controls were those who tested negative. The VE was estimated using non-conditional multiple logistic regression models, adjusting for age (modelled as a natural cubic spline), sex, presence of comorbidities, area of residence, and calendar week (modelled as a natural cubic spline).

Results

Among 20,749 ILI patients tested, 4875 (23.5%) were positive for influenza, with A(H3N2) and B/Victoria being the predominant strains. Adjusted VE was 26.4% (95% CI: 17.8 to 34.1) against any influenza, 22.2% (95% CI: 11.3 to 31.7) against A(H3N2), and 34.7% (95% CI: 19.6 to 47.0) against B/Victoria, with the highest VE observed in adults aged 18-59 years (53.0%, 95%CI: 37.0 to 64.9) against any influenza. The adjusted VE was similar for those vaccinated in 2025/26 only (38.7%, 95%CI: 15.6 to 55.5) or both 2024/25 and 2025/26 seasons (35.1%, 95%CI: 16.5 to 49.6), but higher than those vaccinated in 2024/25 only (17.0%, 95%CI: -16.1 to 40.7) among B/Victoria. For A(H3N2), the VE point estimate was higher among those vaccinated in the 2025/26 season only (27.9%, 95%CI: 11.5 to 41.2) than among those vaccinated in both seasons (17.9%, 95%CI: 4.0 to 29.7) and 2024/25 only (-6.1%, 95%CI: -28.7 to 12.5).

Conclusion

Our findings indicate that seasonal vaccination reduced laboratory-confirmed influenza among outpatients by approximately a quarter, with higher VE in adults aged 18-59 years. VE estimates according to vaccination status over two consecutive seasons showed different patterns for A(H3N2) and B/Victoria. These real-world findings support the ongoing public health value of influenza vaccination and highlight the importance of continuous virological surveillance, prevention, and control policy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.